Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 169 institutions reported holding it in 13F filings for Q3 2026, worth $405.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $431.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $950.0K in total
- 1
- 13F holdersQ3 2026, +13 vs. previous quarter
- 169
- 13F valueReported value at the end of Q3 2026
- $405.4M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $297.2M
- +11.6% year over year
- Net income, FY2025
- -$51.6M
- No comparable prior period
- Free cash flow, FY2025
- -$45.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $78.0M
- +13.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $51.6M (17.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.02M
- Shares sold short
- Change
- −385.7K
- −6.0% vs. previous
- Days to cover
- 9.38
- At average daily volume
Superinvestors holding EOLS, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding EOLS at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Evolus, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)7:04 PM ET | Sep 2 | 2 days | Moatazedi DavidSee Remarks | SSale | −105.1K | $9.04 | −$950.0K | −17.4%499.6K after | |
| Mar 20, 2026 (view filing) | Mar 20 | Same day | Avelar RuiSee Remarks | SSale | −3.12K | $4.75 | −$14.8K | −0.7%427.4K after | |
| Mar 20, 2026 (view filing) | Mar 20 | Same day | Moatazedi DavidSee Remarks | SSale | −13.7K | $4.75 | −$64.9K | −2.2%604.7K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Moatazedi DavidSee Remarks | SSale | −116.7K | $4.89 | −$570.8K | −15.9%618.4K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Avelar RuiSee Remarks | SSale | −30.0K | $4.89 | −$146.7K | −6.5%430.5K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Moatazedi DavidSee Remarks | SSale | −10.5K | $7.15 | −$75.4K | −2.9%354.4K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Avelar RuiSee Remarks | SSale | −2.26K | $7.15 | −$16.2K | −0.6%356.8K after | 10b5-1 |
| Aug 26, 2025 (view filing) | Aug 22 | 4 days | Yamagishi-Dressler TomokoChief Marketing Officer | SSale | −5.72K | $7.51 | −$43.0K | −6.0%89.9K after | 10b5-1 |
| Aug 18, 2025 (view filing) | Aug 15 | 3 days | Stewart BradyDirector | PPurchase | +30.0K | $6.82 | +$204.6K | +51.2%88.6K after | |
| Jun 16, 2025 (view filing) | Jun 13-16 | 3 days | Moatazedi DavidSee Remarks | SSale | −127.9K | $10.03 | −$1.28M | −26.0%364.9K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 169 holdersThe largest institutional positions in Evolus, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6,244,690 | $50.0M | 2.81% | +642,669+11.5% | Added |
| BlackRock, Inc. | 5,315,493 | $42.5M | 0.00% | +474,665+9.8% | Added |
| Soleus Capital Management, L.P. | 5,090,000 | $40.7M | 1.45% | +4,267,572+518.9% | Added |
| Braidwell LP | 3,084,022 | $24.7M | 1.02% | −71,187−2.3% | Reduced |
| Frazier Life Sciences Management, L.P. | 2,630,665 | $21.0M | 0.52% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 2,459,285 | $19.7M | 0.37% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,261,324 | $18.1M | 0.00% | −101,569−4.3% | Reduced |
| State Street Corp | 1,854,107 | $14.8M | 0.00% | +156,813+9.2% | Added |
| Millennium Management LLC | 1,650,372 | $13.2M | 0.01% | −137,557−7.7% | Reduced |
| Geode Capital Management, LLC | 1,580,338 | $12.6M | 0.00% | −28,056−1.7% | Reduced |
Holders of 5% or more of EOLS
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Evolus, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynch Timothy P | 13G/A | 9.90%6.43M shares | +2.00 ppfrom 7.90% | Aug 18, 20253 filings | Feb 17, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G/A | 8.85%5.73M shares | +2.95 ppfrom 5.90% | Feb 14, 20244 filings | Nov 14, 2025 | SEC |
| Soleus Capital Master Fund, L.P. | 13G/A | 7.70%5.09M shares | +2.40 ppfrom 5.30% | Aug 31, 20262 filings | Nov 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.90%4.36M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |